Armata Pharmaceuticals
ARMP
24 hedge funds and large institutions have $3.28M invested in Armata Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
4% more funds holding
Funds holding: 23 → 24 (+1)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
0.06% less ownership
Funds ownership: 3.88% → 3.83% (-0.06%)
15% less capital invested
Capital invested by funds: $3.86M → $3.28M (-$580K)
98% less call options, than puts
Call options by funds: $1K | Put options by funds: $45K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$51.9K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$49.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$6.02K |
| 4 |
CNBT
Cornerstone National Bank & Trust
Palatine,
Illinois
|
+$3.65K |
| 5 |
BlackRock
New York
|
+$2.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$87.5K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$38.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$22.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7.82K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$5.25K |
ARMP Hedge Fund Activity: Q3 2024 in Review
24 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q3 2024, worth a combined $3.28M — down 15% from $3.86M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ARMP positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Group One Trading, opening a new position worth an estimated $51.9K. The largest seller was Susquehanna International Group, cutting an estimated $87.5K.
- 24 institutional investors held Armata Pharmaceuticals (ARMP) as of Q3 2024, up from 23 in Q2 2024.
- Funds reported $3.28M of Armata Pharmaceuticals stock for Q3 2024, down 15% quarter-over-quarter.
- 3 funds opened new Armata Pharmaceuticals positions in Q3 2024 and 2 closed out, a net change of +1 holder.
- The largest Armata Pharmaceuticals buyer in Q3 2024 was Group One Trading, an estimated $51.9K added.
- The largest Armata Pharmaceuticals seller in Q3 2024 was Susquehanna International Group, an estimated $87.5K sold.
Based on aggregated 13F filings for Q3 2024.